Approaches to the Treatment of Initial Pseudomonas aeruginosa Infection in Children Who Have Cystic Fibrosis

Clinics in Chest Medicine

Volumn 28, Issue 2, 2007, Pages 307-318

  Lahiri, Thomas ^a,b  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b FLETCHER ALLEN HEALTH CARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZTREONAM; CARBAPENEM; CARBENICILLIN; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; GENTAMICIN; IMIPENEM; MEROPENEM; TICARCILLIN; TOBRAMYCIN;

BACTERIUM CULTURE; CYSTIC FIBROSIS; DISEASE TRANSMISSION; DRUG EFFICACY; GRAM NEGATIVE INFECTION; HUMAN; LUNG FUNCTION; PATHOGENESIS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW;

ANTI-BACTERIAL AGENTS; CHILD; CYSTIC FIBROSIS; HUMANS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 34247488825     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccm.2007.02.003     Document Type: Review

References (126)

1. Kerem E., Corey M., Gold R., et al. Pulmonary function and clinical course in patients with cystic fibrosis after colonization with Pseudomonas aeruginosa. J Pediatr 116 5 (1990) 714-719
2. Emerson J., Rosenfeld M., McNamara S., et al. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 34 2 (2002) 91-100
3. Li Z., Kosorok M.R., Farrell P.M., et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 293 5 (2005) 581-588
4. Cystic Fibrosis Foundation Patient Registry. 2005 Annual Data Report to the Center Directors; 2006. Bethesda (MD), Cystic Fibrosis Foundation.
5. Doershuk C.F. The Matthews comprehensive treatment program: a ray of hope. In: Doershuk C.F. (Ed). Cystic fibrosis in the 20th Century: people, events, progress (2001), AM Publishing, Ltd, Cleveland (OH) 63-79
6. Burns J.L., Gibson R.L., McNamara S., et al. Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. J Infect Dis 183 3 (2001) 444-457
7. Ratjen F. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis. Curr Opin Pulm Med 12 6 (2006) 428-432
8. Henry R.L., Mellis G.M., and Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol 12 (1992) 158-161
9. Ramsey B.W., Wentz K.R., Smith A.L., et al. Predictive value of oropharyngeal cultures for identifying lower airway bacteria in cystic fibrosis patients. Am Rev Respir Dis 144 2 (1991) 331-337
10. Armstrong D.S., Grimwood K., Carlin J.B., et al. Bronchoalveolar lavage or oropharyngeal cultures to identify lower respiratory pathogens in infants with cystic fibrosis. Pediatr Pulmonol 21 (1996) 267-275
11. Rosenfeld M., Emerson J., Accurso F., et al. Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis. Pediatr Pulmonol 28 5 (1999) 321-328
12. DeBoeck K., Alifer M., and Vandeputte S. Sputum induction in young cystic fibrosis patients. Eur Respir J 16 (2000) 91-94
13. Suri R., Marshall L.J., Wallis C., et al. Safety and use of sputum induction in children with cystic fibrosis. Pediatr Pulmonol 35 4 (2003) 309-313
14. Ordonez C.L., Kartashov A.I., and Wohl M.E. Variability of markers of inflammation and infection in induced sputum in children with cystic fibrosis. J Pediatr 145 5 (2004) 689-692
15. Høiby N. Prospects for the prevention and control of pseudomonal infection in children with cystic fibrosis. Paediatr Drugs 2 6 (2000) 451-463
16. Brett M.M., Ghoneim A.T., and Littlewood J.M. Serum IgG antibodies in patients with cystic fibrosis with early Pseudomonas aeruginosa infection. Arch Dis Child 62 4 (1987) 357-361
17. Brett M.M., Ghoneim A.T., and Littlewood J.M. Prediction and diagnosis of early Pseudomonas aeruginosa infection in cystic fibrosis: a follow-up study. J Clin Microbiol 26 8 (1988) 1565-1570
18. Abman S.H., Ogle J.W., Harbeck R.J., et al. Early bacteriologic, immunologic, and clinical courses of young infants with cystic fibrosis identified by neonatal screening. J Pediatr 119 2 (1991) 211-217
19. West S.E., Zeng L., Lee B.L., et al. Respiratory infections with Pseudomonas aeruginosa in children with cystic fibrosis: early detection by serology and assessment of risk factors. JAMA 287 22 (2002) 2958-2967
20. Pressler T., Frederiksen B., Skov M., et al. Early rise of anti-Pseudomonas antibodies and a mucoid phenotype of Pseudomonas aeruginosa are risk factors for development of chronic lung infection: a case control study. J Cyst Fibros 5 (2006) 9-15
21. Høiby N., Flensborg E.W., Beck B., et al. Pseudomonas aeruginosa infection in cystic fibrosis: diagnostic and prognostic significance of Pseudomonas aeruginosa precipitins determined by means of crossed immunoelectrophoresis. Scand J Respir Dis 58 (1977) 65-79
22. Döring G., and Høiby N. Longitudinal study of immune response to Pseudomonas aeruginosa antigens in cystic fibrosis. Infect Immun 42 (1983) 197-201
23. Pedersen S.S., Espersen F., and Høiby N. Diagnosis of chronic Pseudomonas aeruginosa infection in cystic fibrosis by means of enzyme linked immunosorbent assay. J Clin Microbiol 25 (1987) 1830-1836
24. Cordon S.M., Elborn J.S., and Rayner R.J. IgG antibodies in early Pseudomonas aeruginosa infection in cystic fibrosis. Arch Dis Child 67 6 (1992) 737-740
25. Brett M.M., Simmonds E.J., Ghoneim A.T., et al. The value of serum IgG titres against Pseudomonas aeruginosa in the management of early pseudomonal infection in cystic fibrosis. Arch Dis Child 67 9 (1992) 1086-1088
26. Giordano A., Magni A., Filadoro F., et al. Study of IgG antibodies to Pseudomonas aeruginosa in early cystic fibrosis infection. New Microbiol 21 4 (1998) 375-378
27. DeBoeck K., Eggermont E., Smet M., et al. Specific decrease of anti-pseudomonal IgA after anti-pseudomonal therapy in cystic fibrosis. Eur J Pediatr 154 2 (1995) 157-160
28. Ratjen F., Comes G., Paul K., et al. Effect of continuous antistaphylococcal therapy on the rate of P aeruginosa acquisition in patients with cystic fibrosis. Pediatr Pulmonol 31 1 (2001) 13-16
29. Farrell P.M., Li Z., Kosorok M.R., et al. Bronchopulmonary disease in children with cystic fibrosis after early or delayed diagnosis. Am J Respir Crit Care Med 168 9 (2003) 1100-1108
30. Koyama Y., Kurosawa A., Tsuchiya A., et al. A new antibiotic, colistin, produced by spore-forming soil bacteria. J Antibiot 3 (1950) 457
31. Nord N.M., and Hoeprich P.D. Polymyxin B and colistin: a critical comparison. N Engl J Med 270 (1964) 1030-1035
32. Stern R.C., Doershuk C.F., and Matthews L.W. Use of a heparin lock to administer intermittent intravenous drugs. Clin Pediatr 11 (1972) 521-523
33. Boxerbaum B., Doershuk C.F., and Matthews L.W. Use of carbenicillin in patients with cystic fibrosis. J Infect Dis 122 (1970) S59-S61
34. Phair J.P., Tan T.S., Watanakunakorn C., et al. Carbenicillin treatment of Pseudomonas pulmonary infection: use in children with cystic fibrosis. Am J Dis Child 120 1 (1970) 22-25
35. Crozier D.N., and Khan S.R. Tobramycin in treatment of infections due to Pseudomonas aeruginosa in patients with cystic fibrosis. J Infect Dis 134 (1976) S187-S190
36. Parry M.F., and Neu H.C. Tobramycin and ticarcillin therapy for exacerbations of pulmonary disease in patients with cystic fibrosis. J Infect Dis 134 (1976) S194-S197
37. Parry M.F., Neu H.C., Merlino M., et al. Treatment of pulmonary infections in patients with cystic fibrosis: a comparative study of ticarcillin and gentamicin. J Pediatr 90 1 (1977) 144-148
38. Lau W.K., Young L.S., Osher A.B., et al. Amikacin therapy of exacerbations of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Pediatrics 60 3 (1977) 372-377
39. Kulczycki L.L., Murphy T.M., and Bellanti J.A. Pseudomonas colonization in cystic fibrosis: a study of 160 patients. JAMA 240 1 (1978) 30-34
40. Friis B. Chemotherapy of chronic infections with mucoid Pseudomonas aeruginosa in lower airways of patients with cystic fibrosis. Scand J Infect Dis 11 3 (1979) 211-217
41. Moller N.E., and Høiby N. Antibiotic treatment of chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. Scand J Infect Dis (1981) Supplement 29:87-91
42. Moller N., Eriksen K.R., Feddersen C., et al. Chemotherapy against Pseudomonas aeruginosa in cystic fibrosis: a study of carbenicillin, azlocillin or piperacillin in combination with tobramycin. Eur J Respir Dis 63 2 (1982) 130-139
43. Grenier B., and Gilly R. Azlocillin treatment of Pseudomonas aeruginosa bronchopulmonary infections in children with cystic fibrosis. Presse Med 13 13 (1984) 815-818
44. Penketh A., Hodson M.E., and Gaya H. Azlocillin compared with carbenicillin in the treatment of bronchopulmonary infection due to Pseudomonas aeruginosa in cystic fibrosis. Thorax 39 4 (1984) 299-304
45. Schaad U.B., Desgrandchamps D., and Kraemer R. Antimicrobial therapy of Pseudomonas pulmonary exacerbations in cystic fibrosis: a prospective evaluation of netilmicin plus azlocillin versus netilmicin plus ticarcillin. Acta Paediatr Scand 75 1 (1986) 128-138
46. Paull A., and Morgan J.R. Emergence of ceftriaxone-resistant strains of Pseudomonas aeruginosa in cystic fibrosis patients. J Antimicrob Chemother 18 5 (1986) 635-639
47. Cabezudo I., Thompson R.L., Selden R.F., et al. Cefsulodin sodium therapy in cystic fibrosis patients. Antimicrob Agents Chemother 25 1 (1984) 4-6
48. Heilesen A.M., Permin H., Koch C., et al. Treatment of chronic Pseudomonas aeruginosa infection in cystic fibrosis patients with ceftazidime and tobramycin. Scand J Infect Dis 15 3 (1983) 271-276
49. Moller N.E., Koch C., Vesterhauge S., et al. Treatment of pulmonary Pseudomonas aeruginosa infection in cystic fibrosis with cefsulodin. Scand J Infect Dis 14 3 (1982) 207-211
50. Caplan D.B., and Buchanan C.N. Treatment of lower respiratory tract infections due to Pseudomonas aerguinosa in patients with cystic fibrosis. Rev Infect Dis (1984) 6 Suppl 3:S705-10
51. DeBoeck K., Smet M., and Eggermont E. Treatment of Pseudomonas lung infection in cystic fibrosis with piperacillin plus tobramycin versus ceftazidime monotherapy: preliminary communication. Pediatr Pulmonol 7 3 (1989) 171-173
52. Pedersen S.S., Koch C., Høiby N., et al. An epidemic spread of multiresistant Pseudomonas aeruginosa in a cystic fibrosis centre. J Antimicrob Chemother 17 4 (1986) 505-516
53. Watkins J., Francis J., and Kuzemko J.A. Does monotherapy of pulmonary infections in cystic fibrosis lead to early development of resistant strains of Pseudomonas aeruginosa?. Scand J Gastroenterol (1988) Suppl 143:81-5
54. Dalzell A.M., Sunderland D., Hart C.A., et al. Ceftazidime treatment in cystic fibrosis: resistant organisms in sputum and faeces. Thorax 46 4 (1991) 239-241
55. Govan J.R., Doherty C., and Glass S. Rational parameters for antibiotic therapy in patients with cystic fibrosis. Infection 15 4 (1987) 300-307
56. Reed M.D., Stern R.C., O'Brien C.A., et al. Randomized double-blind evaluation of ceftazidime dose ranging in hospitalized patients with cystic fibrosis. Antimicrob Agents Chemother 31 5 (1987) 698-702
57. DeBoeck K., and Breysem L. Treatment of Pseudomonas aeruginosa lung infections in cystic fibrosis with high or conventional doses of ceftazidime. J Antimicrob Chemother 41 3 (1998) 407-409
58. Rappaz I., Decosterd L.A., Bille J., et al. Continuous infusion of ceftazidime with a portable pump is as effective as thrice-a-day bolus in cystic fibrosis children. Eur J Pediatr 159 12 (2000) 919-925
59. Bernard E., Breilh D., Bru J.P., et al. Is there a rationale for the continuous infusion of cefepime? A multidisciplinary approach. Clin Microbiol Infect 9 5 (2003) 339-348
60. Pedersen S.S., Pressler T., Høiby N., et al. Imipenem/cilastatin treatment of multiresistant Pseudomonas aeruginosa lung infection in cystic fibrosis. J Antimicrob Chemother 16 5 (1985) 629-635
61. Pedersen S.S., Pressler T., Jensen T., et al. Combined imipenem/cilastatin and tobramycin therapy of multiresistant Pseudomonas aeruginosa in cystic fibrosis. J Antimicrob Chemother 19 1 (1987) 101-107
62. Strandvik B., Malmborg A.S., Bergan T., et al. Imipenem/cilastatin, an alternative treatment of pseudomonas infection in cystic fibrosis. J Antimicrob Chemother 21 4 (1988) 471-480
63. Bosso J.A., Saxon B.A., and Matsen J.M. In vitro activity of aztreonam combined with tobramycin and gentamicin against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from patients with cystic fibrosis. Antimicrob Agents Chemother 31 9 (1987) 1403-1405
64. Bosso J.A., Saxon B.A., and Matsen J.M. In vitro activities of combinations of aztreonam, ciprofloxacin, and ceftazidime against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from patients with cystic fibrosis. Antimicrob Agents Chemother 34 3 (1990) 487-488
65. Allen J.E., Bosso J.A., Saxon B.A., et al. Absence of rapidly developing resistance during treatment of cystic fibrosis patients with aztreonam. Diagn Microbiol Infect Dis 8 1 (1987) 51-55
66. Bosso J.A., Allen J.E., and Matsen J.M. Changing susceptibility of Pseudomonas aeruginosa isolates from cystic fibrosis patients with the clinical use of newer antibiotics. Antimicrob Agents Chemother 33 4 (1989) 526-528
67. Blumer J.L., Saiman L., Konstan M.W., et al. The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis. Chest 128 4 (2005) 2336-2346
68. Rubio T.T., and Shapiro C. Ciprofloxacin in the treatment of Pseudomonas infection in cystic fibrosis patients. J Antimicrob Chemother 18 (1986) Suppl D:147-52
69. Rubio T.T. Ciprofloxacin in the treatment of Pseudomonas infection in children with cystic fibrosis. Diagn Microbiol Infect Dis 13 2 (1990) 153-155
70. Lebel M. Fluoroquinolones in the treatment of cystic fibrosis: a critical appraisal. Eur J Clin Microbiol Infect Dis 10 4 (1991) 316-324
71. von Kreutz E., Ruhl-Fehlert C., Drommer W., et al. Effects of ciprofloxacin on joint cartilage in immature dogs immediately after dosing and after a 5-month treatment free period. Arch Toxicol 78 7 (2004) 418-424
72. Grady R. Safety profile of quinolone antibiotics in the pediatric population. Pediatr Infect Dis J 22 12 (2003) 1128-1132
73. Roveta S., Schito A.M., Marchese A., et al. Microbiological rationale for the utilization of prulifloxacin, a new fluoroquinolone, in the eradication of serious infections caused by Pseudomonas aeruginosa. Int J Antimicrob Agents 26 5 (2005) 366-372
74. Bauernfeind A., Emminger G., Horl G., et al. Bacteriological effects of anti-Pseudomonas aeruginosa chemotherapy in cystic fibrosis. Infection 15 5 (1987) 403-406
75. Weiss K., and Lapointe J.R. Routine susceptibility testing of four antibiotic combinations for improvement of laboratory guide to therapy of cystic fibrosis infections caused by Pseudomonas aeruginosa. Antimicrob Agents Chemother 39 11 (1995) 2411-2414
76. Wolter J.M., Bowler S.D., and McCormack J.G. Are antipseudomonal antibiotics really beneficial in acute respiratory exacerbations of cystic fibrosis?. Aust N Z J Med 29 1 (1999) 5-7
77. Smith A.L., Fiel S.B., Mayer-Hamblett N., et al. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest 123 5 (2003) 1495-1502
78. Steinkamp G., Tummler B., Gappa M., et al. Long-term tobramycin aerosol therapy in cystic fibrosis. Pediatr Pulmonol 6 2 (1989) 91-98
79. MacLusky I.B., Gold R., Corey M., et al. Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Pediatr Pulmonol 7 1 (1989) 42-48
80. Wiesemann H.G., Steinkamp G., Ratjen F., et al. Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Pediatr Pulmonol 25 2 (1998) 88-92
81. Smith A.L., Ramsey B.W., Hedges D.L., et al. Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis. Pediatr Pulmonol 7 4 (1989) 265-271
82. Ramsey B.W., Pepe M.S., Quan J.M., et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 340 1 (1999) 23-30
83. Moss R.B. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest 121 1 (2002) 55-63
84. Gibson R.L., Emerson J., McNamara S., et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 167 6 (2003) 841-849
85. Valerius N.H., Koch C., and Høiby N. Prevention of chronic Pseudomonas aeruginosa colonization in cystic fibrosis by early treatment. Lancet 338 8769 (1991) 725-726
86. Frederiksen B., Koch C., and Høiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 23 5 (1997) 330-335
87. Munck A., Bonacorsi S., Mariani-Kurkdjian P., et al. Genotypic characterization of Pseudomonas aeruginosa strains recovered from patients with cystic fibrosis after initial and subsequent colonization. Pediatr Pulmonol 32 4 (2001) 288-292
88. Beringer P. The clinical use of colistin in patients with cystic fibrosis. Curr Opin Pulm Med 7 6 (2001) 434-440
89. Høiby N., Frederiksen B., and Pressler T. Eradication of early Pseudomonas aeruginosa infection. J Cyst Fibros 4 (2005) 49-54
90. Hodson M.E., Gallagher C.G., and Govan J.R. A randomized clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur Respir J 20 3 (2002) 658-664
91. Tamm M., Eich C., Frei R., et al. Inhaled colistin in cystic fibrosis. Schweiz Med Wochenschr 130 39 (2000) 1366-1372
92. Brannon M.K., Pier M., Yeung L., et al. Highly colistin-resistant Pseudomonas aeruginosa as an emerging pathogen in cystic fibrosis. Pediatr Pulmonol (2006) Suppl 29:314
93. Heinzl B., Eber E., Oberwaldner B., et al. Effects of inhaled gentamicin prophylaxis on acquisition of Pseudomonas aeruginosa in children with cystic fibrosis: a pilot study. Pediatr Pulmonol 33 1 (2002) 32-37
94. Schaad U.B., Wedgwood-Krucko J., Suter S., et al. Efficacy of amikacin as adjunct to intravenous combination therapy (ceftazidime and amikacin) in cystic fibrosis. J Pediatr 111 4 (1987) 599-605
95. Kerem E. Mutation specific therapy in cystic fibrosis. Paediatr Respir Rev 7 (2006) Suppl: S166-9
96. Du M., Kelling K.M., Fan L., et al. Clinical doses of amikacin provide more effective suppression of the human CFTR-G542X stop mutation than gentamicin in a CF transgenic mouse model. J Mol Med 84 7 (2006) 573-582
97. Stead R.J., Hodson M.E., and Batten J.C. Inhaled ceftazidime compared with gentamicin and carbenicillin in older patients with cystic fibrosis infected with Pseudomonas aeruginosa. Br J Dis Chest 81 3 (1987) 272-279
98. Gibson R.L., Retsch-Bogart G.Z., Oermann C., et al. Microbiology, safety and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis. Pediatr Pulmonol 41 7 (2006) 656-665
99. Ryan G., Mukhopadhyay S., and Singh M. Nebulised anti-pseudomonal antibiotics for cystic fibrosis. Cochrane Database Syst Rev 3 (2003) CD001021, 2003
100. Koch C. Early infection and progression of cystic fibrosis lung disease. Pediatr Pulmonol 34 3 (2002) 232-236
101. Høiby N. Understanding bacterial biofilms in patients with cystic fibrosis: current and innovative approaches to potential therapies. J Cyst Fibros 1 4 (2002) 249-254
102. VanDevanter D.R., and Van Dalfsen J.M. How much do Pseudomonas biofilms contribute to symptoms of pulmonary exacerbation in cystic fibrosis?. Pediatr Pulmonol 39 6 (2005) 504-506
103. Dalzell A.M., van Saene H.K., and Heaf D.P. Cystic fibrosis, Pseudomonas aeruginosa, and selective decontamination. Arch Dis Child 65 12 (1990) 1365-1367
104. Steinkamp G., Tummler B., Malottke R., et al. Treatment of pseudomonas aeruginosa colonization in cystic fibrosis. Arch Dis Child 64 7 (1989) 1022-1028
105. Littlewood J.M., Miller A.G., and Ghoneim A.T. Nebulised colomycin for early pseudomonas colonization in cystic fibrosis. Lancet 1 8433 (1985) 865
106. Frederiksen B., Koch C., and Høiby N. Changing epidemiology of Pseudomonas aeruginosa infection in Danish cystic fibrosis patients (1974-1995). Pediatr Pulmonol 28 3 (1999) 159-166
107. Taccetti G., Campana S., Festini F., et al. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. Eur Respir J 26 3 (2005) 458-461
108. Ratjen F., Döring G., and Nikolaizik W.H. Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonization in patients with cystic fibrosis. Lancet 358 9286 (2001) 983-984
109. Griese M., Muller I., and Reinhardt D. Eradication of initial Pseudomonas aeruginosa colonization in patients with cystic fibrosis. Eur J Med Res 7 2 (2002) 79-80
110. Steinkamp G., and Ullrich G. Different opinions of physicians on the importance of measures to prevent acquisition of Pseudomonas aeruginosa from the environment. J Cyst Fibros 2 4 (2003) 199-205
111. Banerjee D., and Stableforth D. The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way?. Drugs 60 5 (2000) 1053-1064
112. Canton R., Cobos N., de Garcia J., et al. Antimicrobial therapy for pulmonary pathogenic colonization and infection by Pseudomonas aeruginosa in cystic fibrosis patients. Clin Microbiol Infect 11 9 (2005) 690-703
113. Döring G., Taccetti G., Campana S., et al. Eradication of Pseudomonas aeruginosa in cystic fibrosis patients. Eur Respir J 27 3 (2006) 653
114. Wood D.M., and Smyth A.R. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev 1 (2006) CD004197, 2006
115. Saiman L., and Siegel T. Infection control in cystic fibrosis. Clin Microbiol Rev 17 1 (2004) 57-71
116. Pennington J.E. Preliminary investigations of Pseudomonas aeruginosa vaccine in patients with leukemia and cystic fibrosis. J Infect Dis 130 Suppl 0 (1974) S159-S162
117. Langford D.T., and Hiller J. Prospective, controlled study of a polyvalent pseudomonas vaccine in cystic fibrosis: three year results. Arch Dis Child 59 12 (1984) 1131-1134
118. Lang A.B., Schaad U.B., Rudeberg A., et al. Effect of high-affinity anti-Pseudomonas aeruginosa lipopolysaccharide antibodies induced by immunization on the rate of Pseudomonas aeruginosa infection in patients with cystic fibrosis. J Pediatr 127 5 (1995) 711-717
119. Cryz Jr. S.J., Lang A., Rudegerg A., et al. Immunization of cystic fibrosis patients with a Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine. Behring Inst Mitt 98 (1997) 345-349
120. Cripps A.W., Dunkley M.L., Clancy R.L., et al. Vaccine strategies against Pseudomonas aeruginosa infection in the lung. Behring Inst Mitt 98 (1997) 262-268
121. Keogan M.T., and Johansen H.K. Vaccines for preventing infection with Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev 2 (2000) CD001399, 2000
122. Zuercher A.W., Horn M.P., Que J.U., et al. Antibody responses induced by long-term vaccination with an octovalent conjugate Pseudomonas aeruginosa vaccine in children with cystic fibrosis. FEMS Immunol Med Microbiol 47 2 (2006) 302-308
123. Lang A.B., Rudeberg A., Schoni M.H., et al. Vaccination of cystic fibrosis patients against Pseudomonas aeruginosa reduces the proportion of patients infected and delays time to infection. Pediatr Infect Dis J 23 6 (2004) 504-510
124. Van Wye J.E., Collins M.S., Baylor M., et al. Pseudomonas hyperimmune globulin passive immunotherapy for pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol 9 1 (1990) 7-18
125. Ratjen F., Munck A., and Campello V. Inhaled tobramycin nebuliser solution for treatment of early Pseudomonas aeruginosa infection: first results from the ELITE study. Pediatr Pulmonol (2006) Suppl 29:318
126. Wainwright C., Carlin J., Cooper P., et al. Australasian cystic fibrosis BAL study interim analysis. Pediatr Pulmonol (2006) Suppl 29:317